IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...

The Swiss pharma company also raised its full-year guidance, with sales expected to grow by high-single digits and core ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Novartis’ Vanrafia, a treatment aimed at decreasing proteinuria in adults with primary immunoglobulin A nephropathy ...

The drug, known as atrasentan and sold as Vanrafia, blocks a specific protein in the kidneys known as endothelin A (ETA) receptor, which causes inflammation and cellular damage leading to proteinuria.

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed ...

Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 Phase III data showed ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia ™ (atrasentan), for the reduction of ...